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The global transcriptional proﬁle of peripheral blood mononuclear cells (PBMCs) stimulated with
HIV candidate vaccine (virus-like particles, VLPs) has been evaluated in HIV-infected patients with
low/high viral load compared to healthy volunteers. Baseline activation of chemokine production
was observed in PBMC from HIV-infected patients and innate immune stimulation with HIV-VLPs
was not blunted. The immune proﬁle among HIV-infected patients was found to be qualitatively
similar but quantitatively extremely variable. This diversity was independent of viral load and it
might be dependent on individual immunogenetic traits or concurrent immunological status.
This ex vivo screening strategy represents an efﬁcient tool for guiding modiﬁcations/optimiza-
tions of vaccination strategies and understanding failures in individuals enrolled in clinical trials.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
HIV-1 Pr55gag virus-like particles (VLPs) [1–4] have been
extensively characterized by our group for the ability to induce
maturation and activation of in vitro cultured monocyte-derived
dendritic cells (MDDCs) partly through Toll-like receptor (TLR)-3
and -9 signaling [5]. We observed that the transcriptional proﬁle
of VLP-stimulated MDDCs indicates the reduced transcription of
genes associated with phagocytosis and pathogen recognition
and the activation of genes with function associated with antigen
presentation and MDDCs migration [6]. Similar information can
be observed also in CD14+ uncultured peripheral blood mononu-
clear cells (PBMCs) [7].
Recently, we have demonstrated that HIV-1 seropositivity sta-
tus does not signiﬁcantly impair the immune activation status
and the responsiveness of circulating monocyte CD14+ cell popula-
tions to an immunogenic stimulus [8]. Moreover, Th-1 and Th-2
cytokine production was compared among healthy volunteers,
HIV patients with low and high viral loads demonstrating higher
basal levels of Th2 interleukin (IL)-6 [8].chemical Societies. Published by E
Molecular Biology and Viral
azionale Tumori ‘‘Fond. G.
y. Fax: +39 081 5451276.To better dissect the potential differences in the response of cir-
culating PBMCs from healthy volunteers as well as low and high
viremia HIV-positive subjects to VLPs, in the present study we ap-
plied transcriptional proﬁling to three representative samples from
each of the three categories and tested baseline transcriptional pat-
terns as well as those after stimulation with VLPs or lipopolysac-
charide (LPS) [9].
2. Methods
2.1. Cell culture medium
PBMC culture medium consisted of RPMI 1640 medium (Life
Technologies, Carlsbad, CA) supplemented with 2 mM L-glutamine
(Sigma), 1% nonessential amino acids (Life Technologies), 1% so-
dium pyruvate (Life Technologies), 50 lM 2-mercaptoethanol (Sig-
ma), 50 lg of gentamicin (Life Technologies) per ml, and 10% fetal
calf serum (Life Technologies).
2.2. Patient and donor cohorts, PBMC preparation and treatment
Human specimens were obtained under informed consent, as
approved by the University of Maryland Baltimore Institutional Re-
view Board. Fresh PBMCs were isolated by Ficoll-Hypaque density
gradient centrifugation and plated in 6-well plates at a concentra-
tion of 1  107/well in 3 ml/well volume. PBMCs were stimulatedlsevier B.V. All rights reserved.
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Fig. 1. Self-organizing heat map based on genes with immune annotation according
to Gene Ontology, most differentially expressed in unstimulated PBMCs from
normal volunteers compared to PBMCs stimulated with VLPs or LPS in the same
cohort.
A. Monaco et al. / FEBS Letters 583 (2009) 3004–3008 3005with 6 lg/ml of HIV-VLPs or 1 lg/ml of LPS. Control PBMCs were
added with PBS. The residual endotoxin activity possibly left over
by the VLP preparation was inhibited by pre-incubation with Poly-
mixin B Sulfate (Sigma) at a concentration of 10 lg/ml. After 4 and
8 h the cells were harvested and processed for total RNA
extraction.
2.3. RNA preparation and microarray hybridization
PBMCs were harvested, total RNA and RNA for hybridization
were obtained as previously described [10,11]. Six micrograms of
ampliﬁed test samples aRNA were labeled with Cy5 (Amersham)
while the same amount of reference sample (pooled normal donor
PBMCs) was labeled with Cy3. Test-reference sample pairs were
mixed and co-hybridized to a custom-made 37 K oligo-based
microarray platform encompassing the whole human genome. Ar-
ray data consistency was assessed based on the principle of refer-
ence concordance as previously described [12].
2.4. Microarrays and statistical analyses
Hybridized arrays were scanned at 10-lm resolution on a Gene-
Pix 4000 scanner (Axon Instruments). Resulting jpeg and data ﬁles
were deposited at microarray database (mAdb) (http://nciar-
ray.nci.nih.gov) and retrieved after median centered, ﬁltering of
intensity (>300) and spot elimination (bad and no signal). Data
were further analyzed using the NCI/BRB software [13]. Hierarchi-
cal cluster analysis was conducted on according to Eisen et al. [14];
differential expressed genes were visualized by Treeview and dis-
played according to the central method of normalization [15].
Class comparison was performed using paired or unpaired Stu-
dent’s t test as appropriate. Multivariate analysis was performed
on multiple groups based on the F test with a P-value cutoff of
0.001. Assessment of random identiﬁcation of signiﬁcance was
based on univariate and multivariate permutation test as previ-
ously described [16]. Boolean comparisons were based on the BRB-
Array Software. Fisher’s exact test or v2-test was used to assess the
signiﬁcance of sample distribution among self-organizing classes
of samples as appropriate.
3. Results
3.1. Clinical parameters of the subjects included in the analysis
Eleven subjects were enrolled in the study. Eight were HIV-1-
seropositive, of whom four showed a low HIV-1 viremia (<2.6 log
RNA copies/ml) and four a high viremia (>4.69 log RNA copies/
ml) (SI Table 1). The ﬁrst group was under ART therapy, the latter
enrolled at their ﬁrst visit and naïve for ART treatment. Three
healthy seronegative volunteers were enrolled as controls [8].
3.2. LPS- and VLP-induced activation of PBMC in healthy volunteers
The effect of VLPs and LPS on the activation of PBMCs obtained
from healthy volunteers identiﬁed 560 genes down-regulated and
596 up-regulated by either treatment (multivariate permutation
test < 0.001), with a broad overlap among genes modulated by
LPS and VLPs (Fig. 1).
3.3. Baseline transcriptional patterns of PBMCs
Nine hundred and seventy eight up-regulated genes and 960
down-regulated genes were found differentially expressed in
unstimulated PBMCs from HIV-infected individuals compared to
healthy volunteers. PBMCs of healthy volunteers demonstrated ahighly consistent pattern while PBMCs from HIV-infected individ-
uals displayed a heterogeneous transcriptional patterns and sam-
ples from low- and high-viremia group do not neatly segregate
into two independent clusters (Fig. 2A). Patients 05 and 12 were
excluded from this global analysis, considering that they have been
found anergic according to functional analyses described in our re-
cent paper [8]. However, patient 12 (a high-viremia sample) segre-
gated in between experimental cohorts (red arrow, Fig. 2A), while
patient 05 (a low-viremia sample) segregated with the other sam-
ples from low-viral load patients but displayed a relatively reduced
induction of about 50% of HIV-speciﬁc genes (yellow arrow,
Fig. 2A).
Unstimulated PBMCs from HIV-infected individuals largely re-
ﬂected in baseline conditions the transcriptional proﬁle of PBMCs
from healthy volunteers stimulated ex vivo with VLPs. No tran-
scripts speciﬁcally induced by LPS in vitro in healthy volunteers
were found to be constitutively expressed in vivo by HIV-infected
patients (Fig. 2B).
3.4. Transcription pattern of stimulated PBMCs
The transcriptional proﬁle of PBMCs stimulated with LPS from
healthy volunteers shows signiﬁcant differences with those from
HIV-infected patients, independent of viral load (Fig. 3A).
Fig. 2. (A) Self-organizing heat map representing 1097 genes differentially
expressed in PBMC. The red and yellow arrows points to subjects #12 and #5,
respectively, who were found anergic to VLP-stimulation among the high and low-
viremia patients. (B) Immune genes selected, among those identiﬁed according to
the criteria in panel A, according the list in Fig. 1.
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Fig. 3. Unsupervised hierarchical clustering of PBMC samples stimulated with LPS
(A) or VLPs (B). High stringent ﬁlter was applied resulting in the inclusion of 4,529
cDNA clones. Venn Diagram comparing the overlap of genes differentially expressed
in PBMCs upon stimulation with LPS (B) or VLPs (D).
3006 A. Monaco et al. / FEBS Letters 583 (2009) 3004–3008Boolean comparison of genes differentially expressed in each
cohort identiﬁed predominantly overlapping transcriptional pat-
terns consistent among the three groups with the least overlap be-
tween PBMCs from healthy volunteers and those from HIV-
infected, low-viral load patients (Fig. 3B) [17]. The ISGs modulated
by LPS in the different experimental are shown in SI Table 2.
Similarly, a spontaneous segregation is observed between the
transcriptional proﬁle of PBMCs from healthy volunteers and HIV-
infected individuals stimulated with VLPs (Fig. 3C). The transcrip-
tional patterns of individuals with HIV shows a close overlap in cor-
relative distance (Spearman’s correlation; 1  R2 values) among
patients stimulatedwith LPS (Fig. 3A) orVLPs (Fig. 3C). Boolean com-
parison of genes differentially expressed in response to VLPs identi-
ﬁed overlapping transcriptional patterns among the three cohorts
with the least overlap between PBMCs from normal individuals
and those from HIV-infected, low-viral load patients (Fig. 3D).
In particular, considering speciﬁcally the ISG genes, a multiple
dimensional scaling based on IFNa2b-induced 453 ISGs genes iden-
tiﬁed by our group (Pos et al., manuscript in preparation) clearly
shows a distinct baseline pattern in unstimulated PBMCs from
healthy seronegative and HIV-seropositive subjects as well as a
distinct pattern in VLP-induced PBMCs from the three different
groups (SI Fig. 1). The genes, including ISGs, modulated by VLPs
in the different experimental are shown in SI Table 3.
3.5. Comparison of genes induced by LPS and VLPs
The expression of distinct ISGs genes was stimulated by LPS and
VLPs, while the down regulation of some interferon regulated tran-scripts occurred in common with that induced by VLPs (see SI Ta-
ble 4). On the contrary, the expression of several genes with
immune function was signiﬁcantly affected by LPS and VLP stimu-
lation and are listed according to experimental cohorts (see SI Ta-
ble 5).
In addition, self-organizing maps based on immune genes dif-
ferentially expressed upon LPS and VLP stimulation by the three
groups identiﬁed a cluster of transcripts that included a speciﬁc
sub-group of ISGs (Fig. 4A, orange dashed line a). Reshufﬂing of pa-
tients’ and donors’ sample based on this speciﬁc ISG cluster clearly
predicted a class enriched of LPS-stimulated samples (10 of 11
samples) compared with VLP-stimulated samples (3 of 11 samples)
or unstimulated samples (2 of 11 samples; v2 P-value < 0.001, SI
Fig. 2).
3.6. Patterns of gene expression
The expression of several genes with immune function was sig-
niﬁcantly affected by LPS and VLP and ﬁve distinct patterns of gene
expression were identiﬁed. (1) Genes like IL-6 were not differen-
tially expressed in baseline conditions among experimental co-
horts, but their response to either VLP or LPS was strongly
affected by HIV-status (Fig. 5A). (2) Genes like IL-8 that were very
strongly differentially expressed between HIV patients (up-regu-
lated) compared to healthy volunteers in baseline conditions and
whose post-stimulation levels were partially affected by the HIV-
status (Fig. 5B). (3) Genes like CCL3 whose expression was signiﬁ-
cantly higher in baseline conditions in HIV patients compared to
healthy volunteers and experienced strong up-regulation in re-
sponse to VLP, more than to LPS, in HIV-infected patients more
than in healthy volunteers (Fig. 5C). (4) Genes like CCL22 whose
Fig. 4. (A) Self-organizing heat map based on 156 genes with immune annotations
according to gene ontology modulated at high degree of signiﬁcance by stimulation
with either VLPs or LPS. The orange dashed line emphasizes the ISGs cluster (a); the
blue dashed line emphasizes the lymphokine pattern (b). (B) The yellow and red
arrows point to patient 05 and 12, respectively.
A. Monaco et al. / FEBS Letters 583 (2009) 3004–3008 3007expression was not altered by LPS or VLP stimulation in healthy
volunteers but it was strongly induced by LPS and VLPs in HIV-in-
fected patients independent of viral load (Fig. 5D). (5) Genes like
IRF-7, whose expression was only induced by LPS and it was com-
parable among all experimental cohorts independent of HIV infec-
tion status (Fig. 5E).
3.7. Analysis of range of gene induction
We ﬁnally investigated the dynamic range of gene induction in
response to VLP-stimulation independent of HIV infections status.A
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Fig. 5. (A–E) Relative Cy5/Cy3 values of IL-6, IL-8, CCL3, CCL22 and IRF-7 in different pat
each experimental category. Red, yellow and green boxes indicate high–low-viral load an
respectively) [15].This analysis identiﬁed 133 transcripts whose dynamic range in re-
sponse to VLPs differed signiﬁcantly between HIV-infected patients
and healthy volunteers. A selection of lymphokines among these
genes is shown in SI Fig. 3. Although all patients and donors expe-
rienced increases in the stimulated values of each cytokine, the dy-
namic range was quite different and was strongly affected by the
HIV status independent of viral load. This was particularly evident
for IL-1b and the IL-2R a-chain which were more strongly up-reg-
ulated in HIV-infected patients while the dynamic range was re-
versed for several lymphokines. In spite of this signiﬁcance
difference inD-VLP between healthy donors and HIV-infected indi-
viduals, the cumulative Cy5/Cy3 values in response to VLP stimula-
tion were consistently higher in HIV-infected patients due to their
higher baseline expression.
4. Discussion
The relevance of innate immunity in the natural history of HIV
infection is becoming increasingly recognized [18–22]. To address
the baseline proﬁle of innate immunity and its modulation, we
studied the ex vivo responsiveness of PBMCs to the HIV-VLP vac-
cine molecule and the lipopolysaccharide (LPS), as example of
pathogen associated molecular pattern (PAMP), comparing HIV-in-
fected individuals to normal, healthy volunteers.
According to previous observations [6], the transcriptional acti-
vation of PBMCs in baseline conditions or in response to stimula-
tion with VLPs or LPS recapitulated that observed in MDDCs; this
has important practical implications because ex vivo stimulation
provides a simpliﬁed tool for the analysis of individual patient’s
responsiveness to VLP that does not require extensive in vitro
manipulation. This may be of particular importance considering
the current lack of clinical immunological/biological correlates of
responsiveness of HIV-infected individuals, which may be extre-
mely relevant within the conduction of vaccination protocols.
Transcriptional patterns of PBMC from HIV-infected patients
clearly differed from those of healthy volunteers and signaturesVLP LPS
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d healthy normal controls, respectively. (, ,  = P-value <0.05, <01 and <0.001,
3008 A. Monaco et al. / FEBS Letters 583 (2009) 3004–3008consistent with profound activation of chemokine production were
observed. Interestingly, the RNA expression levels did not always
correlate with those protein expression, reported in our recent pa-
per [8], which are dependent also on external metabolic pathways
affecting either their half life or their compartmentalized
production.
Unexpectedly, in spite of extensive heterogeneity among indi-
vidual patients, several consistent immunological patterns could
be identiﬁed distinguishing HIV-infected individuals from healthy
volunteers that may shed important insights about the immune
biology of HIV infection.
An unexpected observation was the ﬁnding that the IFN-inde-
pendent innate immune response of HIV patients to LPS and VLPs
is not hampered but rather enhanced. In particular, stimulation of
PBMCs from HIV-infected patients with VLPs further enhanced the
innate immune response already ongoing in HIV-infected individ-
uals. A distinct pattern of ISGs induced by VLPs and LPS in PBMCs
from HIV seronegative as well as seropositive subjects may suggest
the need to combine the VLPs with adjuvanting ‘‘LPS-like” mole-
cules for an optimal transient induction of the innate immunity
and, downstream, of the adaptive anti-HIV-1 responses aiming to
an effective viral clearance.
Furthermore, the immune proﬁle among HIV-infected patients
was found to be qualitatively similar but quantitatively extremely
variable and this diversity was independent of viral load suggest-
ing that such differences may be more likely related either to
immunogenetic traits, as recently discussed by Singh et al. [23],
or to concurrent immunological status [24]. This striking variation
should be taken into account when interpreting correlative studies
related to the natural history of the disease or its responsiveness to
therapy.
In summary, this study indicates that this screening approach is
able to identify speciﬁc genomic signatures induced by two dis-
tinct immune activators (HIV-VLPs and LPS) and provides a road
map for the study of HIV-infected patients based on HIV-speciﬁc
signatures, their heterogeneity among patients, their response to
exogenous LPS and VLPs.
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